SCHEMBL15218447

SCHEMBL15218447

CN(CCO)c1ccc(/C=C/C(=O)c2ccc(NC(=O)/C=C/c3ccccc3)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.55
RAB9A P51151 3/20 0.55
KMT2A Q03164 3/20 0.55
NPC1 O15118 2/20 0.55
CASP3 P42574 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
CYP1B1 Q16678 1/20 0.55
SENP8 Q96LD8 1/20 0.55
SENP7 Q9BQF6 1/20 0.55
SENP6 Q9GZR1 1/20 0.55
MEN1 O00255 1/20 0.53
MAPK1 P28482 1/20 0.53
NPSR1 Q6W5P4 2/20 0.53
EGFR P00533 7/20 0.52
MMP1 P03956 6/20 0.52
MMP2 P08253 6/20 0.52
MMP9 P14780 6/20 0.52
MAOA P21397 2/20 0.51
MAOB P27338 2/20 0.51
TUBB4A P04350 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15218333 0.90 TLR9 (0.46) MAPTRAB9AKMT2ANPC1CASP3
SCHEMBL15218411 0.89 MAPT (0.56) MAPTRAB9AKMT2ANPC1CASP3
SCHEMBL30383482 0.89 MAPT (0.61) MAPTRAB9AKMT2ANPC1SMN1; SMN2
SCHEMBL15218408 0.89 MAPT (0.61) MAPTRAB9AKMT2ANPC1SMN1; SMN2
SCHEMBL25196445 0.88 TLR9 (0.46) MAPTRAB9AKMT2ANPC1CASP3
SCHEMBL10046643 0.88 TLR9 (0.46) MAPTRAB9AKMT2ANPC1CASP3
SCHEMBL18960622 0.86 MAPT (0.61) MAPTRAB9AKMT2ANPC1CASP3
SCHEMBL15218197 0.86 MAPT (0.50) MAPTRAB9AKMT2ANPC1CASP3
SCHEMBL15218331 0.86 MAPT (0.61) MAPTRAB9AKMT2ANPC1CASP3
SCHEMBL25194276 0.86 MAPT (0.61) MAPTRAB9AKMT2ANPC1CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed
US-8871976-B2 Chalcone structure fluorescence dye for embryonic stem cell probe NATIONAL UNIVERSITY OF SINGAPORE (SG) 2014-10-28 US disclosed
US-20130224790-A1 Chalcone Structure Fluorescence Dye For Embryonic Stem Cell Probe AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2013-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B MAPT 3297/4885RAB9A 480/4885KMT2A 2792/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 MAPT 3512/4885RAB9A 1327/4885KMT2A 3188/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 MAPT 3512/4885RAB9A 1327/4885KMT2A 3188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.